Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - telmisartan, quantity: 40 mg - tablet - excipient ingredients: sodium stearylfumarate; povidone; mannitol; sodium hydroxide; magnesium stearate; meglumine - telmisartan apel is indicated for: -treatment of hypertension -prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - telmisartan, quantity: 40 mg - tablet - excipient ingredients: sodium stearylfumarate; povidone; mannitol; sodium hydroxide; magnesium stearate; meglumine - telmisartan alsa is indicated for: -treatment of hypertension -prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - telmisartan, quantity: 40 mg - tablet - excipient ingredients: sodium stearylfumarate; povidone; mannitol; sodium hydroxide; magnesium stearate; meglumine - telmisartan ch is indicated for:- treatment of hypertension - prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - telmisartan, quantity: 40 mg - tablet - excipient ingredients: sodium stearylfumarate; povidone; mannitol; sodium hydroxide; magnesium stearate; meglumine - telmisartan ap is indicated for: -treatment of hypertension -prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - telmisartan, quantity: 40 mg - tablet - excipient ingredients: sodium stearylfumarate; povidone; mannitol; sodium hydroxide; magnesium stearate; meglumine - telmisartan agl is indicated for: - treatment of hypertension -prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - telmisartan, quantity: 40 mg - tablet - excipient ingredients: sodium stearylfumarate; povidone; mannitol; sodium hydroxide; magnesium stearate; meglumine - telmisartan alem is indicated for:,? treatment of hypertension in adults,? prevention of cardiovascular morbidity and mortality in adults 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see section 5.1 pharmacodynamic properties, clinical trials)

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - telmisartan, quantity: 40 mg - tablet - excipient ingredients: sodium stearylfumarate; povidone; mannitol; sodium hydroxide; magnesium stearate; meglumine - telmisartan appl is indicated for:- treatment of hypertension, - prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - telmisartan, quantity: 40 mg - tablet - excipient ingredients: sodium stearylfumarate; povidone; mannitol; sodium hydroxide; magnesium stearate; meglumine - telmisartan apa is indicated for:- treatment of hypertension, - prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 25 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: magnesium stearate; meglumine; mannitol; povidone; sodium hydroxide; sodium starch glycollate type a; iron oxide yellow - telmisartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 25 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: iron oxide yellow; mannitol; magnesium stearate; sodium starch glycollate type a; povidone; meglumine; sodium hydroxide - telmisartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension. treatment should not be initiated with these combinations.